Erste Asset Management GmbH Sells 11,885 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Erste Asset Management GmbH reduced its position in IQVIA Holdings by 13.0%, owning 79,467 shares valued at approximately $14.1 million after selling 11,885 shares in Q1.
• Multiple institutional investors have shown varying levels of activity, with Wellington Management increasing its stake by 232.4% and others adjusting their holdings during the same period.
• IQVIA reported an EPS of $2.81, exceeding analysts' expectations and showing a year-over-year revenue increase of 5.3%, setting FY 2025 guidance at 11.750-12.050 EPS.

Erste Asset Management GmbH reduced its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,467 shares of the medical research company's stock after selling 11,885 shares during the period. Erste Asset Management GmbH's holdings in IQVIA were worth $14,105,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. EntryPoint Capital LLC raised its stake in IQVIA by 26.7% during the first quarter. EntryPoint Capital LLC now owns 1,778 shares of the medical research company's stock worth $313,000 after acquiring an additional 375 shares during the period. Fuller & Thaler Asset Management Inc. raised its stake in IQVIA by 29.8% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 6,179 shares of the medical research company's stock worth $1,089,000 after acquiring an additional 1,420 shares during the period. Wellington Management Group LLP raised its stake in IQVIA by 232.4% during the first quarter. Wellington Management Group LLP now owns 32,542 shares of the medical research company's stock worth $5,737,000 after acquiring an additional 22,751 shares during the period. Algert Global LLC acquired a new stake in IQVIA during the first quarter worth about $443,000. Finally, Philadelphia Trust Co. raised its stake in IQVIA by 4.2% during the first quarter. Philadelphia Trust Co. now owns 113,275 shares of the medical research company's stock worth $19,970,000 after acquiring an additional 4,603 shares during the period. Institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

IQV has been the topic of several research reports. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Truist Financial raised their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Price Performance

Shares of IQVIA stock traded up $5.5970 on Friday, hitting $190.9870. The company had a trading volume of 1,619,418 shares, compared to its average volume of 1,441,272. The business has a 50-day simple moving average of $173.70 and a 200-day simple moving average of $168.26. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.47 billion, a PE ratio of 27.64, a PEG ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the firm posted $2.64 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.